Navigation Links
Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Date:6/30/2008

target="_new">http://www.anesiva.com and going to the Investor Information page. A slide presentation that will accompany the call also will be available for download from the Investor Information page. For those unable to participate via the Internet, a 24-hour replay will be available for seven days after the call by dialing (800) 642-1687 (international dial: (706) 645-9291) and giving the following pass code: 53907567.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in two pivotal Phase 3 clinical trials to support an indication for the management of acute pain following orthopedic surgery. Adlea has been shown to reduce pain after only a single administration for weeks to months in multiple settings in mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
2. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
3. Anesiva Announces First Quarter 2008 Financial Results
4. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
5. Anesiva Announces Expansion of Zingo Agreement in Europe
6. Anesiva Announces New Zingo Marketing and Distribution Agreement
7. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
8. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
9. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
10. Anesiva Appoints Daniel Janney to Board of Directors
11. Anesiva Announces Fourth Quarter and Year End 2007 Financial Results Conference Call and February 2008 Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Whitehouse Laboratories is excited to ... with PTI Inspection Systems that will enable ... the art leak testing method development and validation programs ... available. As part of this agreement, Whitehouse Labs has ... Detection Instrument developed and manufactured by PTI. The ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Green & ... in Series B funding and secured Otter Capital as ... capital will accelerate commercialization of GGI’s Agriplier™ technology, building ... types. , “Since our first meeting, we have ... the biological product space,” said Alan Sobba, President and ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
(Date:8/27/2014)... Aug. 27, 2014   MSC , a healthcare ... today announced the appointment of Mary Beth Loesch ... 28 years of experience preparing companies for rapid growth ... Executive Vice President of Corporate Development and Healthcare. In ... business , as well as corporate strategy and marketing. ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2
... Reports Results for the Nine Month Period Ended September ... ... Genmab A/S,(OMX: GEN) announced today results for the nine-month period ended,September 30, ... DKK 667 million (USD 128 million) for the nine,month period ended September ...
... BOSTON, Oct. 29 PAREXEL International,Corporation (Nasdaq: ... services,provider, in partnership with Glenmark Pharmaceuticals Ltd, ... the Good Clinical Practice Journal (GCPj) as,the ... Strategy Award. The,award recognizes the impressive collaborative ...
... announced today the,successful completion of a EUR ... in the development and commercialization of Furanics, ... improvement of,pharmaceutical products. The financing will be ... The focus of the next-generation biofuel,and bioplastic ...
Cached Biology Technology:Genmab Announces Results for the First Nine Months of 2008 2Genmab Announces Results for the First Nine Months of 2008 3Genmab Announces Results for the First Nine Months of 2008 4Genmab Announces Results for the First Nine Months of 2008 5PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy 2PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy 3PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy 4PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy 5Avantium Completes EUR 18 Million Financing Round 2Avantium Completes EUR 18 Million Financing Round 3Avantium Completes EUR 18 Million Financing Round 4
(Date:8/28/2014)... -- Scientists have identified the developmental on-off switch for ... produce more than two-thirds of the world,s naturally derived ... to see whether it is possible to manipulate this ... , The study, appearing August 28 in Cell ... molecule called cyclic-di-GMP and a larger protein called BldD ...
(Date:8/28/2014)... systems are good examples of complex systems. Their ... networkincluding water for cooling, transport to supply fuel, ... step in the network chain is interconnected with ... dependent. A team of UK-based scientists has studied ... The findings have been published in EPJ B ...
(Date:8/28/2014)... . Cars, planes ... of sophisticated assembly lines. Mobile assembly carriers, on to which ... assembly lines. In the case of a car body, the ... a precise spatial and chronological sequence, resulting in a complete ... of such an assembly line at molecular level has been ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Inter-dependent networks stress test 2Nanoscale assembly line 2Nanoscale assembly line 3
... UT Southwestern Medical Center ophthalmologists will be the first in ... to fix nearsightedness. , "Think of it as a contact ... who is inserting the new implantable collamer lens, or ICL, ... , The ICL can replace or reduce the need for ...
... A new UCLA imaging study shows that age-related breakdown ... wiring, correlates strongly with the presence of a key ... are detailed in the January edition of the peer-reviewed ... growing body of evidence that myelin breakdown is a ...
... Survey released a report describing the occurrence of pesticides ... concludes that pesticides are typically present throughout the year ... the Nation, but are less common in ground water. ... at concentrations likely to affect humans. However in ...
Cached Biology News:New 'implanted contacts' designed to fix nearsightedness 2Imaging study links key genetic risk for Alzheimer's disease to myelin breakdown 2Pesticides in the nation's streams and ground water 2Pesticides in the nation's streams and ground water 3Pesticides in the nation's streams and ground water 4
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
P8B1...
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Biology Products: